Results 51 to 60 of about 1,100,787 (194)

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, EarlyView.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]

, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
McCaig, Alison M., Alison M McCaig, Alison M. Mccaig, Cosimo Emilio, Alison M. Michie, Leach Michael T., Alison M Michie, Emilio Cosimo, Michael T. Leach, McCaig Alison M., Michael T Leach, Michie, Alison M., Michie Alison M., Cosimo, Emilio, Leach, Michael T.   +14 more
core   +1 more source

Bruton\u27s tyrosine kinase supports gut mucosal immunity and commensal microbiome recognition in autoimmune arthritis [PDF]

, 2022
Bruton\u27s tyrosine kinase
Thurman, Christina E, Barron, Bridgette B, Reboldi, Andrea, Kendall, Peggy L, Bonami, Rachel H, Verma, Sonam, Nyhoff, Lindsay E, Westlake, Camille S   +7 more
core   +1 more source

PENAPISAN VIRTUAL BERBASIS STRUKTUR DARI DATABASE BAHAN ALAM ZINC SEBAGAI INHIBITOR BRUTON TYROSINE KINASE

JIIS: Jurnal Ilmiah Ibnu Sina, 2019
ABSTRAK   Bruton Tirosin kinase (BTK) memainkan peran penting dalam banyak jalur pensinyalan seluler sehingga menjadikannya target potensial dalam mengobati penyakit autoimun dan kanker.
Fauzan Zein Muttaqin, Wayan Ayu Puje Astuti, La Ode Aman, Ellin Febrina, Aiyi Asnawi   +4 more
doaj   +3 more sources

Mechanisms of adrenocorticotropin-induced activation of erk 1/2 map kinase in the human H295R adrenal cell line [PDF]

, 2008
PhDThe role of ACTH in stimulating or inhibiting growth of adrenal cells has been a subject of some controversy. Reports that ACTH may stimulate Erk/MAP kinase in Y1 cells have suggested a role for cAMP in this process.
Janes, Mandy Elaine
core   +4 more sources

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer [PDF]

, 2007
Tumor angiogenesis is a process that requires migration, proliferation, and differentiation of endothelial cells. We hypothesized that decrease in pancreatic tumor growth due to inhibition of src activity is associated with the inability of src kinase to
Ischenko, Ivan
core   +1 more source

Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy

Therapeutic Advances in Neurological Disorders
Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population.
Afsaneh Shirani, Nil Saez-Calveras, Jack P. Antel, Moein Yaqubi, Wayne Moore, Amy L. Brewster, Olaf Stuve   +6 more
doaj   +1 more source

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma

British Journal of Haematology, EarlyView.
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23–0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort.
Farrukh T. Awan, Ran Liu, Hsin‐Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani   +8 more
wiley   +1 more source

Ibrutinib-associated cutaneous mucormycosis due to an species: report of a case and review of the literature

Therapeutic Advances in Infectious Disease
The use of ibrutinib, a Bruton tyrosine kinase inhibitor, has been associated with invasive fungal infections (IFIs). We describe a case of Apophysomyces infection associated with long-term use of ibrutinib for the treatment of chronic lymphocytic ...
Trung Minh Nguyen, Eva Amenta, Lynne Chapman, Sarvari Yellapragada, Bhuvaneswari Krishnan, Jonathan Lim, Richard J. Hamill   +6 more
doaj   +1 more source